These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24772483)

  • 1. Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes.
    Baker DJ; Atkinson AM; Wilkinson GP; Coope GJ; Charles AD; Leighton B
    Br J Pharmacol; 2014 Apr; 171(7):1629-41. PubMed ID: 24772483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.
    Baker DJ; Wilkinson GP; Atkinson AM; Jones HB; Coghlan M; Charles AD; Leighton B
    Br J Pharmacol; 2014 Apr; 171(7):1642-54. PubMed ID: 24772484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
    Xu J; Lin S; Myers RW; Addona G; Berger JP; Campbell B; Chen HS; Chen Z; Eiermann GJ; Elowe NH; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; Malkani S; McMasters DR; Mitra K; Pachanski MJ; Tong X; Trujillo ME; Xu L; Zhang B; Zhang F; Zhang R; Parmee ER
    Bioorg Med Chem Lett; 2017 May; 27(9):2069-2073. PubMed ID: 28284804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repair of diverse diabetic defects of β-cells in man and mouse by pharmacological glucokinase activation.
    Doliba NM; Fenner D; Zelent B; Bass J; Sarabu R; Matschinsky FM
    Diabetes Obes Metab; 2012 Oct; 14 Suppl 3(0 3):109-19. PubMed ID: 22928571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent clinical advances of glucokinase activators in the treatment of diabetes mellitus type 2.
    Li W; Zhang X; Sun Y; Liu Z
    Pharmazie; 2020 Jun; 75(6):230-235. PubMed ID: 32539915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
    Xu J; Lin S; Myers RW; Trujillo ME; Pachanski MJ; Malkani S; Chen HS; Chen Z; Campbell B; Eiermann GJ; Elowe N; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; McMasters DR; Mitra K; Tong X; Xu L; Zhang F; Zhang R; Addona GH; Berger JP; Zhang B; Parmee ER
    Bioorg Med Chem Lett; 2017 May; 27(9):2063-2068. PubMed ID: 28284809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of high-fat diet on glucose homeostasis and gene expression in glucokinase knockout mice.
    Gorman T; Hope DC; Brownlie R; Yu A; Gill D; Löfvenmark J; Wedin M; Mayers RM; Snaith MR; Smith DM
    Diabetes Obes Metab; 2008 Sep; 10(10):885-97. PubMed ID: 18034843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food.
    Ericsson H; Sjöberg F; Heijer M; Dorani H; Johansson P; Wollbratt M; Norjavaara E
    Diabetes Res Clin Pract; 2012 Dec; 98(3):436-44. PubMed ID: 23010558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
    Eiki J; Nagata Y; Futamura M; Sasaki-Yamamoto K; Iino T; Nishimura T; Chiba M; Ohyama S; Yoshida-Yoshimioto R; Fujii K; Hosaka H; Goto-Shimazaki H; Kadotani A; Ohe T; Lin S; Langdon RB; Berger JP
    Mol Pharmacol; 2011 Dec; 80(6):1156-65. PubMed ID: 21937665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of β-cell genes and improved function in rodent islets following chronic glucokinase activation.
    Gill D; Brocklehurst KJ; Brown HW; Smith DM
    J Mol Endocrinol; 2011 Aug; 47(1):59-67. PubMed ID: 21571864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric activators of glucokinase: potential role in diabetes therapy.
    Grimsby J; Sarabu R; Corbett WL; Haynes NE; Bizzarro FT; Coffey JW; Guertin KR; Hilliard DW; Kester RF; Mahaney PE; Marcus L; Qi L; Spence CL; Tengi J; Magnuson MA; Chu CA; Dvorozniak MT; Matschinsky FM; Grippo JF
    Science; 2003 Jul; 301(5631):370-3. PubMed ID: 12869762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus.
    Grewal AS; Sekhon BS; Lather V
    Mini Rev Med Chem; 2014; 14(7):585-602. PubMed ID: 25052034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and SAR of novel glucokinase activators.
    Cheruvallath ZS; Gwaltney SL; Sabat M; Tang M; Feng J; Wang H; Miura J; Guntupalli P; Jennings A; Hosfield D; Lee B; Wu Y
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2166-71. PubMed ID: 23434031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel glucokinase activators: a patent review (2008 - 2010).
    Sarabu R; Berthel SJ; Kester RF; Tilley JW
    Expert Opin Ther Pat; 2011 Jan; 21(1):13-33. PubMed ID: 21155690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
    Park K; Lee BM; Hyun KH; Lee DH; Choi HH; Kim H; Chong W; Kim KB; Nam SY
    Bioorg Med Chem; 2014 Apr; 22(7):2280-93. PubMed ID: 24588963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
    Krentz AJ; Morrow L; Petersson M; Norjavaara E; Hompesch M
    Diabetes Obes Metab; 2014 Nov; 16(11):1096-101. PubMed ID: 24909093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects.
    Matschinsky FM; Zelent B; Doliba NM; Kaestner KH; Vanderkooi JM; Grimsby J; Berthel SJ; Sarabu R
    Handb Exp Pharmacol; 2011; (203):357-401. PubMed ID: 21484579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans.
    De Ceuninck F; Kargar C; Ilic C; Caliez A; Rolin JO; Umbdenstock T; Vinson C; Combettes M; de Fanti B; Harley E; Sadlo M; Lefèvre AL; Broux O; Wierzbicki M; Fourquez JM; Perron-Sierra F; Kotschy A; Ktorza A
    Br J Pharmacol; 2013 Jan; 168(2):339-53. PubMed ID: 22925001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes.
    Al-Oanzi ZH; Fountana S; Moonira T; Tudhope SJ; Petrie JL; Alshawi A; Patman G; Arden C; Reeves HL; Agius L
    Diabetes Obes Metab; 2017 Aug; 19(8):1078-1087. PubMed ID: 28206714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus.
    Fujieda H; Kogami M; Sakairi M; Kato N; Makino M; Takahashi N; Miyazawa T; Harada S; Yamashita T
    Eur J Med Chem; 2018 Aug; 156():269-294. PubMed ID: 30006171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.